The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry

Authors

  • X. G. L. V. Pouwels Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands; ;Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands; ;School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands
  • S. M. E. Geurts School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands; ;Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands
  • B. L. T. Ramaekers Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands; ;Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands; ;School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands
  • F. Erdkamp Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands
  • B. E. P. J. Vriens Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands
  • K. N. A. Aaldering Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands
  • A. J. van de Wouw Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands
  • M. W. Dercksen Department of Internal Medicine, Máxima Medical Centre, Veldhoven/Eindhoven, The Netherlands
  • T. J. Smilde Department of Internal Medicine, Jeroen Bosch Hospital, Hertogenbosch, The Netherlands
  • N. A. J. B. Peters Department of Internal Medicine, Sint Jans Gasthuis, Weert, The Netherlands
  • J. M. van Riel Department of Internal Medicine, Elisabeth-TweeSteden Hospital, Tilburg, The Netherlands
  • M. J. Pepels Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands
  • J. Heijnen-Mommers School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands; ;Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands
  • M. A. Joore Department of Clinical Epidemiology and Medical Technology Assessment (KEMTA), Maastricht University Medical Centre, Maastricht, The Netherlands; ;Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
  • V. C. G. Tjan-Heijnen School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands; ;Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands
  • M. de Boer School of Oncology and Developmental Biology (GROW), Maastricht University, Maastricht, The Netherlands; ;Division Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands

DOI:

https://doi.org/10.1080/0284186X.2019.1670356

Keywords:

Eribulin, breast neoplasms, matching, genetic matching, relative effectiveness

Abstract

Background: Eribulin provided significant overall survival (OS) benefit in heavily pretreated advanced breast cancer patients in the EMBRACE trial. We investigated the use of eribulin in daily clinical practice, the relative effectiveness of eribulin versus non-eribulin chemotherapy, and the safety of eribulin in real-world patients included in the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry.

Material and methods: Patients treated with eribulin and eligible patients for eribulin who received a different chemotherapy (i.e., non-eribulin group) in ten hospitals in 2013–2017 were included. A multivariate matching algorithm was applied to correct for differences in baseline characteristics between the groups, including the number of previous treatment lines. Progression-free survival (PFS) and OS of eribulin were compared with the matched non-eribulin group through Kaplan-Meier curves and multivariate Cox proportional hazard models. The occurrence of dose delay and reduction was described.

Results: Forty-five patients received eribulin according to its registration criteria and 74 patients were eligible for eribulin but received non-eribulin chemotherapy. Matching increased the similarity in baseline characteristics between the eribulin and non-eribulin groups. Median PFS was 3.5 months (95% confidence interval (CI): 2.7–5.5) in the eribulin group and 3.2 months (95% CI: 2.0–4.8) in the matched non-eribulin group (adjusted hazard ratio (HR): 0.83, 95% CI: 0.49–1.38). Median OS was 5.9 months (95% CI: 4.6–11.0) and 5.2 months (95% CI: 4.6–9.5) in the eribulin and non-eribulin groups, respectively (adjusted HR: 0.66, 95% CI: 0.38–1.13). Dose delay or reduction occurred in 14 patients (31%) receiving eribulin.

Conclusions: No difference in PFS and OS was observed between eribulin and non-eribulin treated patients. Eribulin had a manageable toxicity profile.

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2020-01-02

How to Cite

Pouwels, X. G. L. V. ., Geurts, S. M. E. ., Ramaekers, B. L. T. ., Erdkamp, F. ., Vriens, B. E. P. J. ., Aaldering, K. N. A. ., … Boer, M. de . (2020). The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry. Acta Oncologica, 59(1), 82–89. https://doi.org/10.1080/0284186X.2019.1670356

Issue

Vol. 59 No. 1 (2020): Acta Oncologica

Section

Articles